Regulations.gov document
Annuxure III: Copy of current approved FDA labeling for Neostigmine Methylsulfate…
Supporting & Related Material · FDA-2019-P-1636 · posted Apr 5, 2019
Key facts
| Document ID | FDA-2019-P-1636-0005 |
|---|---|
| Title | Annuxure III: Copy of current approved FDA labeling for Neostigmine Methylsulfate Injection, Solution 3mg/3 mL (1 mg/1mL) NDA 203629 dated November 20, 2018. RE: Citizen Petition from Nexsen Pruet, LLC |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2019-P-1636 |
| Posted | Apr 5, 2019 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: